Drug Discovery

Gut Microbiome Regulates Nanomedicine Delivery to Tumors
Research & Development Gut Microbiome Regulates Nanomedicine Delivery to Tumors

The realization that trillions of microorganisms residing within the human digestive tract exert a profound influence on the systemic distribution of synthetic nanocarriers has completely revolutionized modern oncological strategies. Researchers have shifted their focus from merely optimizing the

Can the Insilico-Bora Alliance Redefine Drug Innovation?
Tech & Innovation Can the Insilico-Bora Alliance Redefine Drug Innovation?

The pharmaceutical industry is entering a period of radical restructuring as the wall between computational design and physical manufacturing finally begins to crumble under the weight of a multi-billion dollar strategic alliance. This partnership between Insilico Medicine and Bora Pharmaceuticals,

New Models Scale Personalized Rare Disease Therapies
Research & Development New Models Scale Personalized Rare Disease Therapies

The pharmaceutical landscape is undergoing a radical transformation as the era of blockbuster drugs for the masses gives way to a highly specialized approach designed for individuals with unique genetic mutations. This paradigm shift was catalyzed by the landmark case of Mila Makovec, who faced a

Can AI Truly Reason in Drug Discovery and Development?
Tech & Innovation Can AI Truly Reason in Drug Discovery and Development?

The pharmaceutical industry is currently witnessing a profound shift where the initial excitement surrounding large language models is finally colliding with the cold, hard reality of clinical trial outcomes and biological complexity. While modern algorithms have become incredibly adept at

Can AI Accelerate Colorectal Cancer Drug Discovery?
Tech & Innovation Can AI Accelerate Colorectal Cancer Drug Discovery?

The pharmaceutical industry has long struggled with the reality that fewer than ten percent of oncology drug candidates successfully navigate the arduous journey from initial discovery to regulatory approval. Colorectal cancer remains a leading cause of mortality globally, yet the traditional

Is LTG-001 the New Standard for Non-Opioid Pain Relief?
Research & Development Is LTG-001 the New Standard for Non-Opioid Pain Relief?

The publication of Phase 2b trial results for Latigo Biotherapeutics’ selective NaV1.8 inhibitor in a leading medical journal signaled a monumental shift in the pursuit of effective, non-addictive pain management alternatives. By successfully targeting the voltage-gated sodium channel with high

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later